O-[4-(2-Dimethylaminoethoxy)-trans-cinnamoyl]fumagillol

Catalog No. :
ACFCIW581
CAS No. :
251111-30-5
Molecular Formula :
C29H41NO6
Molecular Weight :
499.65

IUPAC Name:(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl (E)-3-(4-(2-(dimethylamino)ethoxy)phenyl)acrylate

O-[4-(2-Dimethylaminoethoxy)-trans-cinnamoyl]fumagillol structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameO-[4-(2-Dimethylaminoethoxy)-trans-cinnamoyl]fumagillol
IUPAC Name(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl (E)-3-(4-(2-(dimethylamino)ethoxy)phenyl)acrylate
Molecular FormulaC29H41NO6
Molecular Weight499.65
SMILESO=C(O[C@H](CC1)[C@@H](OC)[C@H]([C@@]2(C)O[C@@H]2CC=C(C)C)[C@]31CO3)/C=C/C4=CC=C(OCCN(C)C)C=C4
InChI KeyZEZFKUBILQRZCK-MJSCXXSSSA-N
Synonym[(3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-yl] (E)-3-[4-(2-dimethylaminoethoxy)phenyl]prop-2-enoate | Beloranib [INN] | BELORANIB [WHO-DD] | 4-Bromoguaiacol, methyl ether | GTPL8445 | SCHEMBL1464
CAS No.251111-30-5
PubChem CID6918502

Synthetic Route by SureRoute

1. ACFCIW581 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACFCIW581 route product structure diagram
    ACFCIW581251111-30-5
Inquiry

2. ACFCIW581 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACNXUH296 route compound structure diagram
    ACNXUH2961774-47-6 In Stock
  4. Then
  5. ACFCIW581 route product structure diagram
    ACFCIW581251111-30-5
Inquiry

Comments (0)